4AB Stock Overview
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 1/6 |
| Financial Health | 3/6 |
| Dividends | 4/6 |
AbbVie Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$170.72 |
| 52 Week High | US$191.96 |
| 52 Week Low | US$125.50 |
| Beta | 0.61 |
| 11 Month Change | -1.89% |
| 3 Month Change | -3.07% |
| 1 Year Change | 34.21% |
| 33 Year Change | 62.90% |
| 5 Year Change | 115.56% |
| Change since IPO | 575.85% |
Recent News & Updates
Recent updates
Shareholder Returns
| 4AB | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 8.6% | -0.7% | 0.2% |
| 1Y | 34.2% | -17.2% | 8.5% |
Return vs Industry: 4AB exceeded the German Biotechs industry which returned -17.2% over the past year.
Return vs Market: 4AB exceeded the German Market which returned 8.5% over the past year.
Price Volatility
| 4AB volatility | |
|---|---|
| 4AB Average Weekly Movement | 4.9% |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.3% |
Stable Share Price: 4AB has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: 4AB's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 50,000 | Robert Michael | www.abbvie.com |
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn’s disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine.
AbbVie Inc. Fundamentals Summary
| 4AB fundamental statistics | |
|---|---|
| Market cap | €300.28b |
| Earnings (TTM) | €4.88b |
| Revenue (TTM) | €53.33b |
61.5x
P/E Ratio5.6x
P/S RatioIs 4AB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4AB income statement (TTM) | |
|---|---|
| Revenue | US$55.53b |
| Cost of Revenue | US$16.47b |
| Gross Profit | US$39.06b |
| Other Expenses | US$33.98b |
| Earnings | US$5.08b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 2.88 |
| Gross Margin | 70.33% |
| Net Profit Margin | 9.15% |
| Debt/Equity Ratio | 1,174.8% |
How did 4AB perform over the long term?
See historical performance and comparisonDividends
3.7%
Current Dividend Yield216%
Payout RatioDoes 4AB pay a reliable dividends?
See 4AB dividend history and benchmarks| AbbVie dividend dates | |
|---|---|
| Ex Dividend Date | Jan 15 2025 |
| Dividend Pay Date | Feb 14 2025 |
| Days until Ex dividend | 50 days |
| Days until Dividend pay date | 80 days |
Does 4AB pay a reliable dividends?
See 4AB dividend history and benchmarks